RecruitingNot ApplicableNCT03233399

Modulating Movement Intention Via Cortical Stimulation

Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures

Sponsor

NYU Langone Health

Enrollment

30 participants

Start Date

Jul 20, 2017

Study Type

INTERVENTIONAL

Conditions

Seizures Seizure Disorder Psychogenic Movement Disorder

Summary

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria5

(Healthy Controls)
Fluent in English
(Patients with PMD or PNES):
Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening

Exclusion Criteria22

Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
Chronic or progressive medical condition
Any history of traumatic brain injury or significant head trauma
Currently meets criteria for substance abuse or dependence
History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
Pregnancy
Metal or devices in the head, including neurostimulators or metal foreign bodies
Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
PMD and PNES Patients
Any history of traumatic brain injury or significant head trauma
Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
Metal or devices in the head, including neurostimulators or metal foreign bodies
Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
Recurrent visual hallucinations, within the past 6 months;
History of significant uncontrollable movements of the head;
Any clinically significant abnormality on vital signs

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESham TMS3 stimulation

half of the subjects will receive sham stimulation first

DEVICErTMS of left or right angular gyrus (AG) or frontal cortex (FC)

Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.

DEVICEAnodal tDCS of left or right AG or FC

Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.